Sherry Cao

2.0k total citations · 1 hit paper
18 papers, 1.1k citations indexed

About

Sherry Cao is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sherry Cao has authored 18 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 9 papers in Cardiology and Cardiovascular Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sherry Cao's work include Coronary Interventions and Diagnostics (13 papers), Cardiac Imaging and Diagnostics (6 papers) and Cardiac Valve Diseases and Treatments (5 papers). Sherry Cao is often cited by papers focused on Coronary Interventions and Diagnostics (13 papers), Cardiac Imaging and Diagnostics (6 papers) and Cardiac Valve Diseases and Treatments (5 papers). Sherry Cao collaborates with scholars based in United States, Netherlands and United Kingdom. Sherry Cao's co-authors include Gregg W. Stone, Krishnankutty Sudhir, Alexandra J. Lansky, Donald E. Cutlip, William Newman, Dean J. Kereiakes, Ali A. Rizvi, Julie Doostzadeh, John Wang and Charles A. Simonton and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Cancer Research.

In The Last Decade

Sherry Cao

18 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease

2010 622 citations Gregg W. Stone, Ali A. Rizvi et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sherry Cao United States	12	1.0k	802	302	288	36	18	1.1k
Julie Doostzadeh United States	8	769 0.7×	596 0.7×	234 0.8×	187 0.6×	35 1.0×	12	822
Masanori Taniwaki Switzerland	19	1.2k 1.1×	754 0.9×	516 1.7×	438 1.5×	24 0.7×	37	1.3k
J Hamburger Netherlands	16	662 0.6×	610 0.8×	326 1.1×	223 0.8×	20 0.6×	43	877
Takeshi Kimura Japan	7	411 0.4×	286 0.4×	199 0.7×	163 0.6×	12 0.3×	19	535
Shing Chiu Wong United States	8	457 0.4×	335 0.4×	170 0.6×	131 0.5×	11 0.3×	14	572
Dirk Mahnkopf Germany	10	475 0.5×	198 0.2×	181 0.6×	271 0.9×	17 0.5×	20	619
Joseph Gelbfish United States	6	309 0.3×	243 0.3×	136 0.5×	101 0.4×	8 0.2×	8	443
Anh B. Bui United States	13	931 0.9×	620 0.8×	683 2.3×	353 1.2×	4 0.1×	24	1.1k
Daniel B. Fram United States	16	439 0.4×	394 0.5×	137 0.5×	146 0.5×	10 0.3×	42	711
Matteo Perfetti Italy	8	217 0.2×	374 0.5×	96 0.3×	53 0.2×	14 0.4×	15	575

Countries citing papers authored by Sherry Cao

Since Specialization

Citations

This map shows the geographic impact of Sherry Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry Cao more than expected).

Fields of papers citing papers by Sherry Cao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry Cao. The network helps show where Sherry Cao may publish in the future.

Co-authorship network of co-authors of Sherry Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry Cao. A scholar is included among the top collaborators of Sherry Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry Cao. Sherry Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kármán, József, Jing Wang, Corneliu Bodea, Sherry Cao, & Marc C. Levesque. (2021). Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms. PLoS ONE. 16(3). e0248889–e0248889. 13 indexed citations

Jin, Liang, Li Li, Chenqi Hu, et al.. (2019). Integrative Analysis of Transcriptomic and Proteomic Profiling in Inflammatory Bowel Disease Colon Biopsies. Inflammatory Bowel Diseases. 25(12). 1906–1918. 22 indexed citations

Theilhaber, Joachim, Stephen F. Madden, Sherry Cao, et al.. (2018). Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy. Cancer Research. 78(13_Supplement). 5550–5550. 1 indexed citations

Bouras, Georgios, Sunny Jhamnani, Vivian G. Ng, et al.. (2016). Clinical outcomes after PCI treatment of very long lesions with the XIENCE V everolimus eluting stent; Pooled analysis from the SPIRIT and XIENCE V USA prospective multicenter trials. Catheterization and Cardiovascular Interventions. 89(6). 984–991. 14 indexed citations

Kimura, Takeshi, Ken Kozuma, Kengo Tanabe, et al.. (2015). A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. European Heart Journal. 36(47). 3332–3342. 196 indexed citations

Richards, Brenda, et al.. (2014). Detection of Adventitious Agents Using Next-Generation Sequencing. PDA Journal of Pharmaceutical Science and Technology. 68(6). 651–660. 9 indexed citations

Dangas, George, Patrick W. Serruys, Dean J. Kereiakes, et al.. (2013). Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. JACC: Cardiovascular Interventions. 6(9). 914–922. 121 indexed citations

Cao, Sherry & Arjen Nikkels. (2013). Dermatologic Manifestations of the LEOPARD Syndrome. The Open Dermatology Journal. 7(1). 11–14. 2 indexed citations

Applegate, Robert J., James Hermiller, Paul Gordon, et al.. (2012). Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents. EuroIntervention. 7(9). 1030–1042. 3 indexed citations

10.

Hermiller, James, Krishnankutty Sudhir, Robert J. Applegate, et al.. (2012). Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention. 8(1). 87–93. 4 indexed citations

11.

Sood, Poornima, Krishnankutty Sudhir, James Hermiller, et al.. (2012). Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents. Circulation Cardiovascular Interventions. 5(2). 150–156. 29 indexed citations

12.

Hermiller, James, Eugenia Nikolsky, Alexandra J. Lansky, et al.. (2011). Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention. 7(3). 307–313. 14 indexed citations

13.

Hermiller, James, Alexandra J. Lansky, Manejeh Yaqub, et al.. (2011). Low Stent Thrombosis Risk with the XIENCE V® Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials. Journal of Interventional Cardiology. 24(4). 326–341. 8 indexed citations

14.

Onuma, Yoshinobu, P. W. Serruys, Susan Veldhof, et al.. (2010). Randomized comparison of everolimus- and paclitaxel-eluting stents: pooled analysis of the 2-year clinical follow-up from the SPIRIT II and III trials. European Heart Journal. 31(9). 1071–1078. 20 indexed citations

15.

Applegate, Robert J., James Hermiller, Jerome Williams, et al.. (2010). Evaluation of the effects of everolimus‐eluting and paclitaxel‐eluting stents on target lesions with jailed side branches: 2‐year results from the SPIRIT III randomized trial. Catheterization and Cardiovascular Interventions. 76(5). 644–651. 14 indexed citations

16.

Stone, Gregg W., Ali A. Rizvi, William Newman, et al.. (2010). Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. New England Journal of Medicine. 362(18). 1663–1674. 622 indexed citations breakdown →

17.

Lansky, Alexandra J., Vivian G. Ng, Ecaterina Cristea, et al.. (2009). Gender‐based evaluation of the XIENCE V™ everolimus‐eluting coronary stent system:. Catheterization and Cardiovascular Interventions. 74(5). 719–727. 34 indexed citations

18.

Gordon, Paul, Robert J. Applegate, James Hermiller, et al.. (2009). Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization and Cardiovascular Interventions. 75(2). 179–186. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact